Skip to main navigation Skip to search Skip to main content

Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer

  • Gary M. Freedman
  • , Penny R. Anderson
  • , Richard J. Bleicher
  • , Samuel Litwin
  • , Tianyu Li
  • , Ramona F. Swaby
  • , Chang Ming Charlie Ma
  • , Jinsheng Li
  • , Elin R. Sigurdson
  • , Deborah Watkins-Bruner
  • , Monica Morrow
  • , Lori J. Goldstein
  • University of Pennsylvania
  • Fox Chase Cancer Center
  • Emory University
  • Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

Purpose: Conventional radiation fractionation of 1.8-2 Gy per day for early stage breast cancer requires daily treatment for 6-7 weeks. We report the 5-year results of a phase II study of intensity modulated radiation therapy (IMRT), hypofractionation, and incorporated boost that shortened treatment time to 4 weeks. Methods and Materials: The study design was phase II with a planned accrual of 75 patients. Eligibility included patients aged ≥18 years, Tis-T2, stage 0-II, and breast conservation. Photon IMRT and an incorporated boost was used, and the whole breast received 2.25 Gy per fraction for a total of 45 Gy, and the tumor bed received 2.8 Gy per fraction for a total of 56 Gy in 20 treatments over 4 weeks. Patients were followed every 6 months for 5 years. Results: Seventy-five patients were treated from December 2003 to November 2005. The median follow-up was 69 months. Median age was 52 years (range, 31-81). Median tumor size was 1.4 cm (range, 0.1-3.5). Eighty percent of tumors were node negative; 93% of patients had negative margins, and 7% of patients had close (>0 and <2 mm) margins; 76% of cancers were invasive ductal type: 15% were ductal carcinoma in situ, 5% were lobular, and 4% were other histology types. Twenty-nine percent of patients 29% had grade 3 carcinoma, and 20% of patients had extensive in situ carcinoma; 11% of patients received chemotherapy, 36% received endocrine therapy, 33% received both, and 20% received neither. There were 3 instances of local recurrence for a 5-year actuarial rate of 2.7%. Conclusions: This 4-week course of hypofractionated radiation with incorporated boost was associated with excellent local control, comparable to historical results of 6-7 weeks of conventional whole-breast fractionation with sequential boost.

Original languageEnglish
Pages (from-to)888-893
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume84
Issue number4
DOIs
StatePublished - Nov 15 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms/pathology
  • Carcinoma in Situ/pathology
  • Combined Modality Therapy/methods
  • Dose Fractionation, Radiation
  • Female
  • Humans
  • Mastectomy, Segmental
  • Middle Aged
  • Neoplasm Recurrence, Local/pathology
  • Neoplasm Staging
  • Neoplasms, Second Primary/pathology
  • Photons/therapeutic use
  • Quality of Life
  • Radiotherapy, Intensity-Modulated/adverse effects
  • Skin/radiation effects
  • Time Factors
  • Tumor Burden

Fingerprint

Dive into the research topics of 'Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer'. Together they form a unique fingerprint.

Cite this